Acute Crit Care.  2024 Nov;39(4):652-653. 10.4266/acc.2023.00983.e1.

Corrigendum to: Comparative evaluation of tocilizumab and itolizumab for treatment of severe COVID-19 in India: a retrospective cohort study

• Kumar A
• Kumar N
• Pattanayak A
• Kumar A
• Palavesam S
• Nagaraju PM
• Das R

• KMID: 2563556
• DOI: http://doi.org/10.4266/acc.2023.00983.e1

Reference

1. Kumari P, Sinha C, Kumar A, Kumar A, Shettru KA, Kandrakonda PK. Comparative study of tocilizumab versus itolizumab in coronavirus disease 2019-infected patients: a randomized controlled trial. Res Opin Anesth Intensive Care. 2023; 10:1–6.

2. Kumar S, De Souza R, Nadkar M, Guleria R, Trikha A, Joshi SR, et al. A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19. Expert Opin Biol Ther. 2021; 21:675–86.